Andrew Tsai
Stock Analyst at Jefferies
(0)
# 4723
Out of 5,270 analysts
20
Total ratings
26.67%
Success rate
-21.85%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Rocket Pharmaceutica... | Initiates Coverage On: Buy | 29 | 8.81 | 229.17% | 1 | Dec 18, 2024 | |
Marinus Pharma | Downgrades: Hold | 5 1 | n/a | n/a | 1 | Oct 25, 2024 | |
Sarepta Therapeutics | Initiates Coverage On: Buy | 165 | 101.19 | 63.06% | 1 | Oct 21, 2024 | |
Relmada Therapeutics | Upgrades: Buy | 4 13 | 0.26 | 4900% | 2 | Sep 17, 2024 | |
Rapport Therapeutics | Initiates Coverage On: Buy | 35 | 7.16 | 388.83% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 33 | 3.14 | 950.96% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 1 15 | 2.5 | 500% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 3 | 0.3 | 900% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 32 3 | 0.37 | 710.81% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 23 16 | 22.13 | -27.7% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | 2.19 | 813.24% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 55 70 | 131.27 | -46.67% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 27 | 1.5 | 1700% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | n/a | n/a | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 16 23 | 35.7 | -35.57% | 1 | Jun 1, 2020 |